||MT2006-13 Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL)
||This clinical trial is studying how well an autologous stem cell transplant works in treating patients with acute myeloid leukemia.
||Patients will receive chemotherapy, G-CSF, undergo bone marrow harvest or peripheral blood stem cell collection, total body irradiation (as applicable) and stem cell transplantation. After completion of study treatment, patients are followed periodically for 5 years.
||Giving chemotherapy and colony-stimulating factors, such as G-CSF, may increase the number of stem cells in the blood for collection and freezing. Chemotherapy and radiation therapy are given to prepare for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation.
||Patient must have a diagnosis of acute non-lymphoctyic leukemia (acute myeloid leukemia) and have achieved a 1st or 2nd bone marrow remission.
|Applicable Disease Sites
||Acute myeloid leukemia (AML)
||Blood and Marrow Transplant
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
FILGRASTIM (G-CSF, NEUPOGEN)
||Masonic Cancer Center
||Patient must be no more than 70 years of age. Must be in remission during peripheral blood stem cell collection or marrow harvest. Patients must have adequate organ function. A signed informed consent and HIPAA authorization are required; an assent form is also required if patient is a minor.